Anteris Technologies initiated with a Buy at Lake Street

Lake Street initiated coverage of Anteris Technologies (AVR) with a Buy rating and $20 price target Anteris’ DurAVR transcatheter heart valve “provides a holy grail value proposition” of fastest and most predictable delivery paired with “impressive” hemodynamics and laminar flow, the analyst tells investors. DurAVR’s early clinical data “has supported a best of both worlds proposition,” which is something existing commercial valves have “struggled to achieve,” says the analyst, who notes that Anteris is expected to enroll the first patients in the 1,000-patient pivotal trial in Q3 of this year with approval expected by mid-2028.